Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2000-11-28
2003-01-14
Siew, Jeffrey (Department: 1637)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S022100, C435S006120, C435S007100, C435S091100, C435S091200
Reexamination Certificate
active
06506890
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a device which produces compacted nucleic acid in a reproducible, pharmaceutical context for use in gene therapy studies and treatments, and more particularly unimolecular DNA.
BACKGROUND OF THE INVENTION
Genetic engineering broadly, and gene therapy studies, in particular, involve the genetic transformation of living host cells by introduction of exogenous materials such as foreign DNA to the host cells to change or modulate the host cells. When successful, the genes carried by the foreign DNA are expressed in the host cells, and thus, the host cells are transformed. Genetically transformed cells or tissues are of great value in research, medicine and agriculture.
There are several conventional gene transfer techniques which are routinely used such as cell fusion, electroporation, liposome fusion, calcium phosphate precipitation, viral infection, conjugal transfer, micropipette microinjection and aerosol beam microinjection. While much research is dedicated to gene transfer techniques, all of these conventional transfer technologies deal with DNA, DNA/liposome or DNA/protein particles in large, noncondensed forms. Noncondensed DNA particles are less stable since there are nucleases in blood which can destroy noncondensed DNA, and noncondensed DNA particles are likely too large to fit into a cellular endosome following receptor-mediated endocytosis, or to be transported into the nucleus of post-mitotic cells. Therefore, the effective transfer of genes remains an obstacle in many fields of research.
It has been recognized that DNA particles in condensed form are more effective in successfully delivering the DNA payload to target tissues while remaining stable and permitting receptor-mediated endocytosis. With this recognition, the literature teaches adding DNA and condensing proteins together while mixing, generally at low concentrations of each. This produces condensed DNA particles called &psgr;-form DNA which consists of approximately 10-50 molecules of DNA and many molecules of condensing proteins. A laboratory method for the production of &psgr;-DNA is described in Perales, et al.,
Biochemical and Functional Characterization of DNA Complexes Capable of Targeting Genes to Hepatocytes via the Asialoglycoprotein Receptor
, J. of Biological Chemistry, vol. 272, pp.7398-7407, which is herein incorporated by reference. These &psgr;-DNA particles have a size on the order of 100 to 200 nm which are improved over noncondensed particles, but do not completely eliminate the stability, efficiency and specificity problems of the larger particles altogether.
Condensation of DNA particles to smaller sizes than &psgr;-DNA has been heretofore achieved manually by highly trained individuals in a lab. A preferred form of DNA particles which are condensed even smaller than the &psgr;-DNA is unimolecular, which refers to DNA complexes which consist of a single unit of DNA plasmid; these particles are referred to as compacted DNA particles to distinguish them from condensed DNA particles which consist more typically of multiple molecules of DNA. Due to the multiple steps of such a manual procedure and the number of variables inherent in the operation, the successful production of compacted DNA particles is more akin to an art form practiced by a few qualified individuals rather than a repeatable pharmaceutical production method. These unimolecular formulations of compacted DNA are stable, and, compared to other formulations, more effectively transfer DNA to the nucleus of target tissues following intravenous and other routes of administration.
One of the limitations of conventional gene transfer techniques has been the size of DNA particles which are introduced to target tissues. The instability of large DNA particles and the unsatisfactory level of gene transfer with conventional condensed DNA particles have prompted the use of smaller, compacted forms of DNA particles. A discussion of compacted nucleic acids and their delivery to cells as well as the advantages of using compacted DNA is disclosed in commonly assigned U.S. Pat. Nos. 5,844,107 and 5,877,302, the entire disclosures of which are hereby incorporated by reference. Since the production of compacted DNA manually is expensive, time-consuming and sometimes inconsistent, there is a need for an automated device which produces compacted, unimolecular DNA particles in a controlled, pharmaceutical production method.
SUMMARY OF THE INVENTION
Accordingly, it is a principal object of the present invention to provide an automated DNA compaction device which produces unimolecularly compacted DNA particles in an unaggregated formulation.
Another object of the present invention is to provide a series of automated steps to produce compacted DNA particles consistently and repeatedly
A further object of the invention is to provide a control system for an automated DNA compaction device.
Directed to achieving these objects, an automated nucleic acid compaction device is provided which is a real-time measuring and mixing instrument operating as a closed loop system in either automatic or manual mode. Broadly, the device includes the following components: a support and agitation system; a measuring and testing system; and a dispensing system; all controlled by a control system. The control system controls the support and agitation system and the dispensing system based either on a predetermined formulation or by analysis of feedback data provided by the measuring and testing system. Once a desired level of nucleic acid compaction is reached, the control system ensures that dispensing and agitation, if applicable, are ceased so that the compacted nucleic acid can be removed from the device.
In a preferred embodiment the support and agitation system of the compaction device comprises a vortexing device such as a magnetic stirring table for supporting a beaker of a nucleic acid solution into which nixing solutions are dispensed during the compaction process. The nucleic acid and mixing solutions are disclosed in U.S. Pat. Nos. 5,844,107 and 5,877,302. It is to be understood that the nucleic acid may be a DNA, RNA, or a DNA or RNA derivative such as a derivative resistant to degradation in vivo as discussed in the patents.
The measuring and testing system of the compaction device comprises a probe disposed in the beaker of initial batch solution and a monitoring device coupled to the control system for iterative feedback of readings to the control system.
The dispensing system of the compaction device comprises pumps and stepper motors to operate micro-liter syringes which dispense additive solutions into the beaker. The dispensing system also comprises a dispersion system in the form of a sonication device to disperse the additive solutions. The control system commands the dispensing system.
The control system of the compaction device comprises a CPU and operational software which receives readings from the measuring and testing system, analyzes the data and compares the data to initial readings and desired readings, and signals the dispensing system to dispense additive solution to the batch solution if necessary. In this manner, precise control over the additive solution is maintained by the control system.
REFERENCES:
patent: 3780992 (1973-12-01), Nishi et al.
patent: 4046515 (1977-09-01), de Leeuw
patent: 4341736 (1982-07-01), Drbal et al.
patent: 4612291 (1986-09-01), Dawes
patent: 4911556 (1990-03-01), Lim et al.
patent: 4927062 (1990-05-01), Walsh
patent: 4930898 (1990-06-01), Miller-Ihli
patent: 5122342 (1992-06-01), McCulloch et al.
patent: 5240842 (1993-08-01), Mets
patent: 5354844 (1994-10-01), Beug et al.
patent: 5365798 (1994-11-01), Kressirer
patent: 5480772 (1996-01-01), Wangh
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5544535 (1996-08-01), Thomas
patent: 5612205 (1997-03-01), Kay et al.
patent: 5614503 (1997-03-01), Chaudhary et al.
patent: 5625561 (1997-04-01), Kato et al.
patent: 5641680 (1997-06-01), Zhao
patent: 5651981 (1997-07-01), Ashley et al.
patent: 5661018 (1997
Cooper Mark J.
Kowalczyk Tomasz H.
Pasumarthy Murali Krishna
Banner & Witcoff , Ltd.
Siew Jeffrey
LandOfFree
Method of nucleic acid compaction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of nucleic acid compaction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of nucleic acid compaction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3029312